Merck chopping 140-plus staffers out of Acceleron in wake of $11.5B buyout

Four months after Merck closed its $11.5 billion acquisition of Acceleron, the pharma giant helped cover the tab by chopping out more than 140 staffers from the newly acquired biotech. But they’re not all getting pink slipped. Around 120 Acceleron employees now have new posts inside Merck, the pharma giant tells us.

Merck posted a WARN notice on the layoffs this week, alerting the state of Massachusetts of plans to cut 170 staffers in Cambridge, MA. At the end of 2020, Acceleron had 312 full timers.

A spokesperson for Merck tells Endpoints News:

On Tuesday, March 15, Merck issued a Worker Adjustment and Retraining Notification Act (“WARN”) notice to 143 legacy employees of Acceleron Pharma who will be separating from the company in a phased manner through November 18, 2022.

Around the time of the acquisition, employees were either offered a full-time role or were asked to remain to…
Click here to view original post